Daily equity-report by epic research 25 feb 2013

download Daily equity-report by epic research 25 feb 2013

of 4

  • date post

    20-Oct-2014
  • Category

    Documents

  • view

    165
  • download

    1

Embed Size (px)

description

 

Transcript of Daily equity-report by epic research 25 feb 2013

-=6 HEADLINES

Indian Market

Indian equity markets were down 0.03%

Nifty down by 1.95 pts and settle at 5850.30

Sensex down by 8.35 pts at 19317.01

Bank Nifty up by 19.60 pts at 12100.50

Global Market

European markets were up with FTSE up by 48.51 closed at 6340 ,CAC up by 46.81 closed at 3671 and DAX up by 41.73 closed at 7625.

Dow future was up 34.00 closed at

13906.00

WWW.EPICRESEARCH.CO 09752199966

DAILY EQUITY NEWSLETTER 25TH FEBRUARY 2013

HEADLINES

RBI officials fear Budget choices give

less room for rate cuts

Jet Airways falls 5% on concerns over

Etihad deal

SME: Channel Nine Entertainment IPO

opens for subscription

Ex-Infosys executive aims to shake up IT

industry billing model

FIIs and DIIs

CATEGORY DATE BUY SELL NET

FII 22-Feb-13 2864.02 2583.72 280.3

DII 22-Feb-13 937.21 1289.19 -351.98

NIFTY DAILY PIVOTS

PIVOT R4 R3 R2 R1 PP S1 S2 S3 S4

NIFTY 6103 6026 5949 5900 5872 5823 5795 5718 5641

WWW.EPICRESEARCH.CO 09752199966

MARKET ANALYSIS:

Key benchmark indices reversed intraday gains and slipped into the red in late trade as index heavyweight ITC dropped and as another index heavyweight Reliance Industries (RIL) trimmed

intraday gains. The market breadth, indicating the overall health of the market, turned negative from

positive in late trade, having alternately moved between positive and negative zone throughout the

trading session.

BSE Sensex was down 16.20 points or 0.08% to 19,309.16. CNX Nifty was down 3.90 points or 0.07% to 5,848.35. Among the 30-share Sensex pack, 16 stocks gained while the rest of them declined. Sun Pharmaceutical Industries rose 2.04% to Rs 811.90 after striking a record high of Rs 814.20 in

intraday trade today, 22 February 2012. State run National Thermal Power Corporation (NTPC) rose

0.16%. NTPC has tied up a term loan facility of $250 million with State Bank of India, New York

Branch and Mizuho Corporate Bank, Singapore Branch as Arrangers and Lenders. The loan agreement

signed in New York by Mr. A.K. Singhal, Director (Finance), empowers NTPC for utilization of the

proceeds of the loan towards capital expenditure for procurement of goods and services for the ongoing

and new projects and renovation and modernization of power generation stations of the company. Bhel

took over BHPV as its 100% subsidiary in 2008. However, the company's performance was not upto

the mark, as it remained a separate company and it could not derive full benefits of synergy with Bhel.

STOCKS TO WATCH

ANDHRA BANK

AUROBINDO PHARMA

AMBUJA

BHARTI AIRTEL

SCRIPS IN BAN PERIOD

HDIL

PUNJLYOD

SUZLON

RENUKA

WELCORP

WWW.EPICRESEARCH.CO 09752199966

.

EXPERT OPINION

NIFTY

Nifty looks Consolidate

Strategy: Sell on rise

Support: 5800

Resistance: 5900

BANK NIFTY

Bank Nifty looks Consolidate

Strategy: Sell on rise

Support: 12040

Resistance: 12170

460

.0

GAINERS AND LOOSERS

PREVIOUS PERFORMANCE

TYPE SCRIP B/S RESULT

CASH ADANI POWER

S NOT

EXECUTED

CASH SESA GOA S SL TRIGERRED

FUTURE PUNJ LLYOD S SL TRIGERRED

FUTURE RELIANCE POWER

S SL TRIGERRED

UPCOMING RESULTS

PANTALOON

DHANUSH TECH

DAILY NIFTY GAINERS

SCRIPS RATE VOL.

(000)

PR.

CLOSE

NET

CHAN

GE

%

CHANG

E

Bharti Airtel

309.65 6409.00 296.20 13.45 4.54

DLF 281.45 13577.50 272.45 9.00 3.30

Wipro 415.95 2171.76 405.80 10.15 2.50

Power Grid

109.05 7905.51 106.85 2.20 2.06

Sun Pharma

811.55 1284.90 797.50 14.05 1.76

DAILY NIFTY LOOSERS

SCRIPS RATE VOL.

(000)

PR.

CLOSE

NET

CHAN

GE

%

CHAN

GE

Hindustan Unilever

455.40 2420.05 468.25 -12.85 -2.74

Coal India

331.70 2323.29 340.30 -8.60 -2.53

JP Associate

70.25 35866.74 71.80 -1.55 -2.16

Maruti Suzuki

1438.40 648.68 1467.50 -29.10 -1.98

HDFC 799.85 2776.08 815.05 -15.20 -1.86

.

MARKET CALLS

CASH

SCRIPS ACTION LEVEL 1ST

TARGET 2ND

TARGET STOP LOSS

ANDHRA BANK SELL 99.30 98.80 98.00 99.80

BHARTI AIRTEL BUY 309.90 311.90 314.90 307.90

FUTURE

SCRIPS ACTION LEVEL 1ST

TARGET 2ND

TARGET STOP LOSS

AUROBINDO PHARMA

SELL 180.35 179.35 177.85 181.35

AMBUJA BUY 198.90 199.90 200.90 197.90

Disclaimer

The information and views in this report, our website & all the service we provide are believed to be reliable, but we do not accept any responsibility (or liability) for errors of fact or opinion. Users have the right to choose the product/s that suits them the most.

Sincere efforts have been made to present the right investment perspective. The information contained herein is based on analysis and up on sources that we consider reliable.

This material is for personal information and based upon it & takes no responsibility

The information given herein should be treated as only factor, while making investment decision. The report does not provide individually tailor-made investment advice. Epic research recommends that investors independently evaluate particular investments and strategies, and encourages investors to seek the advice of a financial adviser. Epic research shall not be responsible for any transaction conducted based on the information given in this report, which is in violation of rules and regulations of NSE and BSE.

The share price projections shown are not necessarily indicative of future price performance. The information herein, together with all estimates and forecasts, can change without notice. Analyst or any person related to epic research might be holding positions in the stocks recommended. It is understood that anyone who is browsing through the site has done so at his free will and does not read any views expressed as a recommendation for which either the site or its owners or anyone can be held responsible for . Any surfing and reading of the information is the acceptance of this disclaimer.

All Rights Reserved. Investment in equity & bullion market has its own risks.

We, however, do not vouch for the accuracy or the completeness thereof. we are not responsible for any loss incurred whatsoever for any financial profits or loss which may arise from the recommendations above epic research does not purport to be an invitation or an offer to buy or sell any financial instrument. Our Clients (Paid Or Unpaid), Any third party or anyone else have no rights to forward or share our calls or SMS or Report or Any Information Provided by us to/with anyone which is received directly or indirectly by them. If found so then Serious Legal Actions can be taken.